Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
19-Aug-2026 | 810 | 819 | 802.35 | 807.75 | 26,691 | 50,05,53,492.7 | 3,02,713 |
20-Aug-2026 | 814 | 834.1 | 808.35 | 820.95 | 41,755 | 1,07,90,72,353.55 | 5,91,089 |
21-Aug-2026 | 825 | 825 | 810.3 | 814.95 | 26,764 | 58,12,32,923.95 | 3,45,231 |
24-Aug-2026 | 819 | 866.65 | 811.25 | 855.8 | 93,651 | 2,55,19,38,998.8 | 8,83,364 |
25-Aug-2026 | 859 | 869 | 835.5 | 861.55 | 43,486 | 1,02,26,69,972.05 | 3,30,506 |
26-Aug-2026 | 864 | 868.4 | 851.05 | 860.75 | 32,646 | 63,05,75,891.6 | 3,01,130 |
27-Aug-2026 | 860.75 | 919 | 858.65 | 901.85 | 51,129 | 2,00,81,15,846.15 | 10,47,149 |
28-Aug-2026 | 901 | 910 | 890.7 | 903.8 | 33,099 | 79,23,73,817.6 | 3,93,742 |
31-Aug-2026 | 907.15 | 950 | 873.2 | 949.3 | 63,203 | 2,39,60,40,862.5 | 9,82,800 |
01-Sep-2026 | 950 | 952 | 874 | 889.7 | 80,249 | 2,01,32,70,496.4 | 8,47,267 |
02-Sep-2026 | 889 | 930.85 | 887.05 | 928.55 | 48,025 | 1,34,51,23,590.55 | 6,24,530 |
03-Sep-2026 | 935 | 966.45 | 923.6 | 956.15 | 72,290 | 1,77,61,81,431.45 | 7,80,512 |
04-Sep-2026 | 956.15 | 973.9 | 946.2 | 964.15 | 24,194 | 62,90,30,552.05 | 2,47,704 |
07-Sep-2026 | 974 | 980.1 | 923 | 939.5 | 41,302 | 1,02,54,61,986.95 | 4,67,784 |
08-Sep-2026 | 949.85 | 965 | 937.1 | 959.9 | 24,063 | 68,15,65,846.5 | 2,62,592 |
09-Sep-2026 | 959.9 | 974.95 | 954.1 | 960.6 | 26,432 | 66,87,36,399.55 | 3,32,360 |
10-Sep-2026 | 968.95 | 974 | 931.3 | 939.9 | 31,557 | 65,05,77,034.25 | 3,25,308 |
11-Sep-2026 | 935 | 975 | 910 | 961.15 | 56,245 | 1,40,13,21,256.9 | 3,56,574 |
15-Sep-2026 | 968 | 968.75 | 902.25 | 911.9 | 35,157 | 70,36,81,334.6 | 3,23,705 |
16-Sep-2026 | 909.9 | 945 | 874.85 | 928.05 | 51,170 | 1,08,18,03,973.6 | 4,38,907 |
17-Sep-2026 | 923 | 963 | 923 | 958.35 | 38,709 | 78,06,32,241.75 | 3,97,903 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
